Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”

Downregulation of ATM1 affects iron-sulfur cluster proteins in <i>Toxoplasma</i> and iron levels in <i>Plasmodium</i>. by Deepti Shrivastava (17715780)

“…Unchanged proteins are displayed in black, while significantly altered proteins are displayed in grey (< 1.5-fold change (FC), local false discovery rate, LFDR < 0.05) or in blue (>1.5-fold increased; LFDR < 0.05) or red (> 1.5-fold decreased; LFDR < 0.05). …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…Four patients had no significant clinical changes. Six patients experienced marked improvement. …”

Table 1_Exploring the alleviating effects of Bifidobacterium metabolite lactic acid on non-alcoholic steatohepatitis through the gut-liver axis.docx by Hongmei Zhao (250090)

“…</p>Results<p>In vivo findings indicated that, in comparison to CBX group (Control group without antibiotic treatment), NAFLD/CBX group (NAFLD group without antibiotic administration) and NAFLD/ABX group (NAFLD group with antibiotic administration) exhibited increased liver-to-body weight ratio, higher lipid droplet accumulation, aggravated liver histopathological damage, and elevated levels of AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase), TC (Total Cholesterol), TG (Triglycerides), LDL-C (Low-Density Lipoprotein Cholesterol), IL-6 (Interleukin-6), TNF-α (Tumor Necrosis Factor-alpha), IL-1β (Interleukin-1 beta), and NLRP3-related molecules, while HDL-C (High-Density Lipoprotein Cholesterol) levels significantly decreased. Intervention with Bifidobacterium significantly reversed these adverse changes. …”

Data Sheet 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 5_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 6_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Data Sheet 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Image 4_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.tif by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Data Sheet 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…</p>Results<p>Between 1999 and 2023, a total of 357,606 deaths from esophageal cancer were recorded. A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Data Sheet 1_N6-methyladenosine RNA landscape in the aged mouse hearts.zip by Xia Jing (3255219)

“…</p>Results<p>The overall m6A level remained constant; however, the expression of the methyltransferase METTL14 and the demethyltransferase FTO were significantly upregulated in aged hearts. Knockdown of METTL14 alleviated H₂O₂-induced senescence phenotypes, as reflected by a reduction in the number of SA-β-gal positive cells and a decrease in p21 expression. …”

Data Sheet 2_N6-methyladenosine RNA landscape in the aged mouse hearts.zip by Xia Jing (3255219)

“…</p>Results<p>The overall m6A level remained constant; however, the expression of the methyltransferase METTL14 and the demethyltransferase FTO were significantly upregulated in aged hearts. Knockdown of METTL14 alleviated H₂O₂-induced senescence phenotypes, as reflected by a reduction in the number of SA-β-gal positive cells and a decrease in p21 expression. …”

Data Sheet 3_N6-methyladenosine RNA landscape in the aged mouse hearts.zip by Xia Jing (3255219)

“…</p>Results<p>The overall m6A level remained constant; however, the expression of the methyltransferase METTL14 and the demethyltransferase FTO were significantly upregulated in aged hearts. Knockdown of METTL14 alleviated H₂O₂-induced senescence phenotypes, as reflected by a reduction in the number of SA-β-gal positive cells and a decrease in p21 expression. …”

Data Sheet 4_N6-methyladenosine RNA landscape in the aged mouse hearts.pdf by Xia Jing (3255219)

“…</p>Results<p>The overall m6A level remained constant; however, the expression of the methyltransferase METTL14 and the demethyltransferase FTO were significantly upregulated in aged hearts. Knockdown of METTL14 alleviated H₂O₂-induced senescence phenotypes, as reflected by a reduction in the number of SA-β-gal positive cells and a decrease in p21 expression. …”

Data Sheet 1_Global, regional and national mortality burden of laryngeal cancer attributable to occupational exposure to sulfuric acid and asbestos: 1990–2021 and projections to 20... by Xin Gong (592328)

“…Disease burden varies significantly across SDI regions, suggesting that preventive measures should be tailored to specific SDI levels.…”

Data Sheet 3_Global, regional and national mortality burden of laryngeal cancer attributable to occupational exposure to sulfuric acid and asbestos: 1990–2021 and projections to 20... by Xin Gong (592328)

“…Disease burden varies significantly across SDI regions, suggesting that preventive measures should be tailored to specific SDI levels.…”

Data Sheet 2_Global, regional and national mortality burden of laryngeal cancer attributable to occupational exposure to sulfuric acid and asbestos: 1990–2021 and projections to 20... by Xin Gong (592328)

“…Disease burden varies significantly across SDI regions, suggesting that preventive measures should be tailored to specific SDI levels.…”